Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Achromobacter xylosoxidans

ABSTRACT: Achromobacter xylosoxidans comparative genomics

PROVIDER: PRJNA343957 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	MJMN01.dat.gz	Other
	MJMN01.fasta.gz	Fasta.gz
	MJMN01.master.dat	Other
	MJMO01.dat.gz	Other
	MJMO01.fasta.gz	Fasta.gz

Items per page:

1 - 5 of 12

Similar Datasets

Pathogenesis of Achromobacter xylosoxidans respiratory infections: colonization and persistence in vivo and differential gene expression in cystic fibrosis sputum

Project description:The goals of this study were to determine differential gene expression between Achromobacter xylosoxidans clinical isolate Ax 7 in a synthetic artificial sputum media compared to a rich media control (LB).

2023-12-14 | GSE235679 | GEO

Achromobacter xylosoxidans

Project description:Achromobacter xylosoxidans overview

| PRJNA38809 | ENA

The Achromobacter xylosoxidans type VI secretion system 2 (T6SS): from clinical to molecular evidences of its 3 implication in cystic fibrosis

Project description:Bacteria of the genus Achromobacter are environmental germs, with an unknown reservoir, which can become opportunistic pathogens in immunocompromised patients, and be responsible for bacteremia, meningitis, pneumonia and peritonitis. Achromobacter xylosoxidans is an emerging pathogenic bacterium frequently isolated in the context of cystic fibrosis (CF). Recent studies show that A. xylosoxidans is involved in the degradation of the respiratory function of CF patients. The respiratory ecosystem of CF patients is colonized by bacterial species that constantly fight for space and access to nutrients. In particular, these bacteria use an antagonism system, a type VI secretion nanomachine (T6SS), which represents a virulence factor in many pathogenic bacteria. This study aimed to investigate the prevalence of the T6SS genes in Achromobacter xylosoxidans isolated in cystic fibrosis patient. We also evaluated clinical and molecular characteristics of T6SS-positive A. xylosoxidans strains. We have shown that A. xylosoxidans possesses a T6SS-encoded gene cluster and that some environmental and clinical isolates assemble a functional T6SS nanomachine. The A. xylosoxidans T6SS is used to target competitor bacteria, including other CF-specific pathogens. We gathered some evidences pointing toward a role of T6SS in CF-lung colonization: i, CF mimicking conditions trigger the activation of A. xylosoxidans T6SS; ii, we detected Hcp in the sputum of CF patient and iii, the T6SS helps internalization of A. xylosoxidans in lung epithelial cells. Our study highlights a new clinical determinant of the virulence of A. xylosoxidans as well as new diagnostic and therapeutic options in cystic fibrosis.

2024-02-01 | PXD031682 | Pride

Achromobacter xylosoxidans

Project description:Achromobacter xylosoxidans Genome sequencing

| PRJNA245784 | ENA

Achromobacter xylosoxidans sequencing

Project description:Achromobacter xylosoxidans sequencing

| PRJEB10827 | ENA

Achromobacter xylosoxidans

Project description:Achromobacter xylosoxidans Genome sequencing and assembly

| PRJNA390198 | ENA

Achromobacter xylosoxidans

Project description:Achromobacter xylosoxidans Genome sequencing and assembly